Oncolytic adenovirus armed with shRNA targeting MYCN gene inhibits neuroblastoma cell proliferation and in vivo xenograft tumor growth

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 6, 2013, Pages 933-941

  Li, Yuan ^a   Zhang, Baofu ^b   Zhang, Hongwei ^a   Zhu, Xiaoyu ^a   Feng, Dongchuan ^a   Zhang, Deyong ^a   Zhuo, Baobiao ^a   Li, Liantao ^b   Zheng, Junnian ^b  

^a XUZHOU CHILDREN S HOSPITAL   (China)

^b XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

MYCN; Neuroblastoma; Oncolytic adenovirus; Short hairpin RNA

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; E1A PROTEIN; ENHANCED GREEN FLUORESCENT PROTEIN; MYC PROTEIN; ONCOLYTIC ADENOVIRUS; ONCOLYTIC ADENOVIRUS ZD 55 SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG IDENTIFICATION; GENE EXPRESSION REGULATION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE C MYB; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COMBINED MODALITY THERAPY; GENE EXPRESSION; HEK293 CELLS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84878284102     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1406-4     Document Type: Article

References (35)

1. Au T, Thorne S, Korn WM, Sze D, Kirn D, Reid TR (2007) Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver. Cancer Gene Ther 14(2):139-150. doi: 10.1038/sj.cgt.7700988
2. Chesler L, Goldenberg DD, Collins R, Grimmer M, Kim GE, Tihan T, Nguyen K, Yakovenko S, Matthay KK, Weiss WA (2008) Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction. Neoplasia 10(11):1268-1274
3. Feng C, Wang T, Tang R, Wang J, Long H, Gao X, Tang S (2010) Silencing of the MYCN gene by siRNA delivered by folate receptor-targeted liposomes in LA-N-5 cells. Pediatr Surg Int 26(12):1185-1191. doi: 10.1007/s00383-010-2703-5
4. Garcia-Castro J, Alemany R, Cascallo M, Martinez-Quintanilla J, Arriero Mdel M, Lassaletta A, Madero L, Ramirez M (2010) Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study. Cancer Gene Ther 17(7):476-483. doi: 10.1038/cgt.2010.4
5. Guse K, Hemminki A (2009) Cancer gene therapy with oncolytic adenoviruses. J BUON Official J Balkan Union Oncol 14(Suppl 1):S7-15
6. Hara J (2012) Development of treatment strategies for advanced neuroblastoma. Int J Clin Oncol/Jpn Soci Clin Oncol. doi: 10.1007/s10147-012- 0417-5
7. Henderson TO, Bhatia S, Pinto N, London WB, McGrady P, Crotty C, Sun CL, Cohn SL (2011) Racial and ethnic disparities in risk and survival in children with neuroblastoma: a Children's Oncology Group study. J Clin Oncol Official J Am Soc Clin Oncol 29(1):76-82. doi: 10.1200/JCO.2010.29.6103
8. Jiang R, Xue S, Jin Z (2011) Stable knockdown of MYCN by lentivirus-based RNAi inhibits human neuroblastoma cells growth in vitro and in vivo. Biochem Biophys Res Commun 410(2):364-370. doi: 10.1016/j.bbrc.2011.06.020
9. Kang JH, Rychahou PG, Ishola TA, Qiao J, Evers BM, Chung DH (2006) MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells. Biochem Biophys Res Commun 351(1):192-197. doi: 10.1016/j.bbrc.2006.10.020
10. Keshelava N, Zuo JJ, Chen P, Waidyaratne SN, Luna MC, Gomer CJ, Triche TJ, Reynolds CP (2001) Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res 61(16):6185-6193
11. Kroesen M, Lindau D, Hoogerbrugge P, Adema GJ (2012) Immunocombination therapy for high-risk neuroblastoma. Immunotherapy 4(2):163-174. doi: 10.2217/imt.11.169
12. Li H, Dutuor A, Tao L, Fu X, Zhang X (2007) Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma. Clin Cancer Res Official J Am Assoc Cancer Res 13(1):316-322. doi: 10.1158/1078-0432.CCR-06-1625
13. Lu X, Pearson A, Lunec J (2003) The MYCN oncoprotein as a drug development target. Cancer Lett 197(1-2):125-130
14. Mahller YY, Williams JP, Baird WH, Mitton B, Grossheim J, Saeki Y, Cancelas JA, Ratner N, Cripe TP (2009) Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS ONE 4(1):e4235. doi: 10.1371/journal.pone.0004235
15. Maris JM (2010) Recent advances in neuroblastoma. N Engl J Med 362(23):2202-2211. doi: 10.1056/NEJMra0804577
16. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, Gerbing RB, London WB, Villablanca JG (2009) Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol Official J Am Soc Clin Oncol 27(7):1007-1013. doi: 10.1200/JCO.2007.13. 8925
17. McCormick F (2003) Cancer-specific viruses and the development of ONYX-015. Cancer Biol Ther 2(4 suppl 1):S157-S160
18. Nara K, Kusafuka T, Yoneda A, Oue T, Sangkhathat S, Fukuzawa M (2007) Silencing of MYCN by RNA interference induces growth inhibition, apoptotic activity and cell differentiation in a neuroblastoma cell line with MYCN amplification. Int J Oncol 30(5):1189-1196
19. Navalkele P, O'Dorisio MS, O'Dorisio TM, Zamba GK, Lynch CF (2011) Incidence, survival, and prevalence of neuroendocrine tumors versus neuroblastoma in children and young adults: nine standard SEER registries, 1975-2006. Pediatr Blood Cancer 56(1):50-57. doi: 10.1002/pbc.22559
20. Pearson AD, Pinkerton CR, Lewis IJ, Imeson J, Ellershaw C, Machin D, European Neuroblastoma Study G, Children's C, Leukaemia G (2008) High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol 9(3):247-256. doi: 10.1016/S1470-2045(08)70069-X
21. Pei DS, Di JH, Chen FF, Zheng JN (2010) Oncolytic-adenovirus-expressed RNA interference for cancer therapy. Expert Opin Biol Ther 10(9):1331-1341. doi: 10.1517/14712598.2010.512002
22. Pesonen S, Helin H, Nokisalmi P, Escutenaire S, Ribacka C, Sarkioja M, Cerullo V, Guse K, Bauerschmitz G, Laasonen L, Kantola T, Ristimaki A, Rajecki M, Oksanen M, Haavisto E, Kanerva A, Joensuu T, Hemminki A (2010) Oncolytic adenovirus treatment of a patient with refractory neuroblastoma. Acta Oncol 49(1):117-119. doi: 10.3109/02841860903071369
23. Ramirez M, Garcia-Castro J, Alemany R (2010) Oncolytic virotherapy for neuroblastoma. Discov Med 10(54):387-393
24. Rothmann T, Hengstermann A, Whitaker NJ, Scheffner M, zur Hausen H (1998) Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol 72(12):9470-9478
25. Schor NF (1999) Neuroblastoma as a neurobiological disease. J Neurooncol 41(2):159-166
26. Tonini GP, Pistoia V (2006) Molecularly guided therapy of neuroblastoma: a review of different approaches. Curr Pharm Des 12(18):2303-2317
27. Toyoda H, Yin J, Mueller S, Wimmer E, Cello J (2007) Oncolytic treatment and cure of neuroblastoma by a novel attenuated poliovirus in a novel poliovirus-susceptible animal model. Cancer Res 67(6):2857-2864. doi: 10.1158/0008-5472.CAN-06-3713
28. Van Maerken T, Vandesompele J, Rihani A, De Paepe A, Speleman F (2009) Escape from p53-mediated tumor surveillance in neuroblastoma: switching off the p14(ARF)-MDM2-p53 axis. Cell Death Differ 16(12):1563-1572. doi: 10.1038/cdd.2009.138
29. Weber A, Starke S, Bergmann E, Christiansen H (2006) The coamplification pattern of the MYCN amplicon is an invariable attribute of most MYCN-amplified human neuroblastomas. Clin Cancer Res Off J Am Assoc Cancer Res 12(24):7316-7321. doi: 10.1158/1078-0432.CCR-06-0837
30. Wei N, Fan JK, Gu JF, He LF, Tang WH, Cao X, Liu XY (2009) A double-regulated oncolytic adenovirus with improved safety for adenocarcinoma therapy. Biochem Biophys Res Commun 388(2):234-239. doi: 10.1016/j.bbrc.2009.07. 142
31. Westermark UK, Wilhelm M, Frenzel A, Henriksson MA (2011) The MYCN oncogene and differentiation in neuroblastoma. Semin Cancer Biol 21(4):256-266. doi: 10.1016/j.semcancer.2011.08.001
32. Woo CW, Tan F, Cassano H, Lee J, Lee KC, Thiele CJ (2008) Use of RNA interference to elucidate the effect of MYCN on cell cycle in neuroblastoma. Pediatr Blood Cancer 50(2):208-212. doi: 10.1002/pbc.21195
33. Xue C, Haber M, Flemming C, Marshall GM, Lock RB, MacKenzie KL, Gurova KV, Norris MD, Gudkov AV (2007) p53 determines multidrug sensitivity of childhood neuroblastoma. Cancer Res 67(21):10351-10360. doi: 10.1158/0008-5472.CAN-06-4345
34. Zhang ZL, Zou WG, Luo CX, Li BH, Wang JH, Sun LY, Qian QJ, Liu XY (2003) An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Res 13(6):481-489. doi: 10.1038/sj.cr.7290191
35. Zheng JN, Pei DS, Sun FH, Zhang BF, Liu XY, Gu JF, Liu YH, Hu XL, Mao LJ, Wen RM, Liu JJ, Li W (2009) Inhibition of renal cancer cell growth by oncolytic adenovirus armed short hairpin RNA targeting hTERT gene. Cancer Biol Ther 8(1):84-91